Figures & data
Figure 1 The study profile of the retrospective research regarding anlotinib monotherapy for patients with previously treated advanced or metastatic esophageal squamous cell carcinoma.
Table 1 Demographic and Clinical Characteristics of the 83 Patients with Advanced or Metastatic ESCC According to Hypertension Status
Figure 2 Waterfall plot for the best percentage change in target lesion of the 83 patients with advanced or metastatic esophageal squamous cell carcinoma who received anlotinib monotherapy (blue columns represent PR, black columns represent SD and red columns represent PD in the best overall response).
Figure 3 The CT scan results of the changes for target lesions in esophagus and lung sites of one patient with esophageal squamous cell carcinoma before and after the administration of anlotinib monotherapy.
Figure 4 The progression-free survival curve of the 83 patients with advanced or metastatic esophageal squamous cell carcinoma who received anlotinib monotherapy.
Table 2 Univariate Analysis Between PFS of the 83 Patients with ESCC and Baseline Characteristic Subgroups
Figure 5 The overall survival curve of the 83 patients with advanced or metastatic esophageal squamous cell carcinoma who received anlotinib monotherapy.
Table 3 Safety Profile of the 83 Patients with ESCC Who Received Anlotinib Monotherapy
Figure 6 The progression-free survival curve of the 83 patients with advanced or metastatic esophageal squamous cell carcinoma who received anlotinib monotherapy according to hypertension status.
Table 4 Multivariate Cox Analysis for PFS Based on Baseline Characteristic and Hypertension Status